Startseite Universitätsklinikum Heidelberg Startseite Universitätsklinikum Heidelberg
Personen

DR. KAVITA SINGH


SENIOR RESEARCHER

Kavita Singh is a trained epidemiologist, and health systems researcher with expertise in clinical trials, implementation science, and economic evaluation. Her research focuses on the intersection of chronic non-communicable diseases, infectious diseases, implementation research and social health protection in low- and middle-income countries. She specializes in the design and impact evaluation of health system interventions aimed at bridging the evidence to practice gaps. Kavita employs a wide range of research methods, including experimental and quasi-experimental designs, as well as qualitative approaches, often integrated into mixed-methods studies that are closely aligned with real-world global health practice. In 2019, Kavita was awarded the Emerging Global Leader Award, a career development grant from the Fogarty International Centre, National Institutes of Health, USA, to develop and test the feasibility and impact of a multicomponent intervention for cardiovascular disease prevention in India.

In addition to her role at HIGH, Kavita is an Adjunct Assistant Professor at the Rollins School of Public Health, Emory University, Atlanta, USA.

Wissenschaftlicher Werdegang

2018: PhD in Chronic Disease Epidemiology, All India Institute of Medical Sciences, New Delhi, India

2016: PhD, All India Institute of Medical Sciences, New Delhi, India

2013: Economic Evaluation Course, London School of Hygiene and Tropical Medicine, UK

2008: Masters in Clinical Research, Cranfield University, United Kingdom

2006: Bachelors in Science (Microbiology, Hons), University of Delhi, India

PROJECTS & GRANTS

  1. European and Developing Countries Clinical Trials Partnership (EDCTP), EU Horizon, “Closing the immunization gap by reaching zero-dose children through improved equitable and cost-effective vaccine delivery strategies (REACH-OUT)”; 2025 –2028
  2. Advancing Research Opportunities at the Intersection of Cardiovascular Health and Planetary Health. GLOHRA Scientific Workshop Grant. Dec 2024
  3. Applied Implementation science research in global healthcare, systems, policy settings. German Alliance for Global Health Research (GLOHRA) Global Health Academy. Training Grant. Oct 2024.
  4. Medical Data Scientist Fellowship, Medical Faculty, Heidelberg University, Germany. “Cardiovascular health across the life course in diverse populations”. 2023-2026.
  5. Fogarty International Centre, National Institutes of Health, USA, “Developing and testing Collaborative Quality ImProvement initiative for prevention of cardiovascular disease in India (C-QIP Study)”; 2019 – 2025.
  6. Kreditanstalt für Wiederaufbau (KfW), Germany, “Effectiveness and economic evaluation of a modified program for cervical cancer screening in Cambodia assisted by a cloud-based digital system; 2022 –2025.
  7. World Heart Federation (WHF), Geneva, Switzerland, “Guidelines for management of Long COVID in patients with cardiovascular diseases; 2023 – 2025.
  8. Northwestern University, USA, “The International Study of Cardiovascular Health Metrics (INTERMET) 2: Implementation of a Protocol for Population Research and Primary Care Practice in LMICs; 2023 –2025.
  9. Servier, France, and Imperial College London, UK, “Treatment Optimisation for blood Pressure with Single-Pill combinations in India (TOPSPIN)”; 2021 – 2024.
  10. Department of Biotechnology, India, and MRC, UK “CARDINNATE: Variation in innate immune activation and cardiovascular disease risk as drivers of immune pathology in COVID19 outcome in South Asians in UK and India”; 2021 – June 2024.
  11. Deutsche Gesellschaft für Internationale Zusammenarbeit GmbH (GIZ), Germany, “Implementation Research to Evaluate Ghana Heart Initiative”; 2022 –2023.
  12. World Heart Federation COVID-19 and Cardiovascular Disease Study; 2020 –2024.

Selected Publications

  1. Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial. Singh K, Nikhare K, Gandral M, et al. American Heart Journal. 2024;276:83-98. doi:10.1016/j.ahj.2024.07.008 
  2. Effect of a multicomponent quality improvement strategy on sustained achievement of diabetes care goals and macrovascular and microvascular complications in South Asia at 6.5 years follow-up: Post hoc analyses of the CARRS randomized clinical trial. Ali MK*, Singh K*, Kondal D, et al. PLOS Medicine. 2024;21(6):e1004335. Published 2024 Jun 3. doi:10.1371/journal.pmed.1004335. 
  3. Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study. Singh K, Kondal D, Mohan S, et. al. BMC Public Health. 2021 Apr 8;21(1):685. 
  4. Collaborative Quality Improvement Strategy in Secondary Prevention of Cardiovascular Disease in India: Findings from a Multi-Stakeholder, Qualitative Study using Consolidated Framework for Implementation Research (CFIR). Singh K, Huffman MD, Johnson LCM, et al. Global Heart. 2022;17(1):72. Published 2022 Oct 11. doi:10.5334/gh.1161
  5. Assessment of Studies of Quality Improvement Strategies to Enhance Outcomes in Patients with Cardiovascular Disease. Singh K, Bawa VS, Venkateshmurthy NS, et al. JAMA Network Open. 2021 Jun 1;4(6):e2113375.  URL to full list of publications: I have more than 80 peer-reviewed research publications (h-index: 39). Google scholar: https://scholar.google.co.in/citations?view_op=list_works&hl=en&user=k8C76hwAAAAJ